This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
Allakos Inc. is a clinical-stage biotechnology company developing therapeutic antibodies for allergic, inflammatory, and fibrotic diseases. Its core research and development activities involve preclinical and clinical testing of biologic drug candidates, which inherently requires animal testing to establish safety and efficacy for regulatory approval. The company's operations are centered on laboratory research, as evidenced by its lease agreements for laboratory space.
The company's lead product candidate, an antibody targeting Siglec-8, has been the subject of published preclinical research involving animal experiments. A 2021 study in *Nature Communications* on nanoparticle technology related to Siglec-8 explicitly notes that "all animal experiments were performed in accordance with protocols" and lists a scientific advisory board member from Allakos among its authors. This indicates the company's direct involvement in and reliance on animal-based research models to advance its drug pipeline.
As a pharmaceutical research entity with no marketed products, Allakos's business model is fundamentally predicated on animal testing to generate the data required for clinical trials and eventual regulatory filings. This places the company within the scope of commercial animal exploitation for research and development purposes.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.